Cumberland Partners Ltd Lowers Stake in IQVIA Holdings Inc. $IQV

Cumberland Partners Ltd cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 21.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,005 shares of the medical research company’s stock after selling 2,713 shares during the quarter. Cumberland Partners Ltd’s holdings in IQVIA were worth $1,706,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in IQV. Vanguard Group Inc. raised its stake in IQVIA by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock valued at $4,429,426,000 after acquiring an additional 159,899 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of IQVIA by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock valued at $982,272,000 after purchasing an additional 24,453 shares during the last quarter. Boston Partners grew its stake in shares of IQVIA by 14.9% in the 4th quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock valued at $923,276,000 after purchasing an additional 530,672 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of IQVIA by 16.2% during the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock worth $856,468,000 after purchasing an additional 528,753 shares during the last quarter. Finally, Invesco Ltd. raised its stake in shares of IQVIA by 15.3% during the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock worth $526,891,000 after purchasing an additional 367,204 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on IQV shares. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Evercore restated an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. Robert W. Baird lifted their target price on shares of IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a report on Wednesday, July 1st. Wall Street Zen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, HSBC restated a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a research report on Monday, July 6th. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $225.71.

IQVIA Trading Up 0.4%

NYSE:IQV opened at $208.22 on Friday. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $247.04. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The stock has a fifty day moving average price of $188.23 and a two-hundred day moving average price of $187.38. The stock has a market capitalization of $34.75 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 1.86 and a beta of 1.20.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business’s revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the firm earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its board has initiated a stock repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.